Evidence map›Paper›PMID 42236477›Full record

ArticleNature communications2026

MYOD1 mutation drives cancer stem cell pathways and therapy-resistance in spindle cell/sclerosing rhabdomyosarcoma.

Yun Wei, Luis Antonio Corchete Sánchez, Sabateeshan Mathavarajah, Diego Antelo, Shuze Wang, Jihee Lee, Alexander Daiki Weissman, Devika D Kannambadi, Qian Qin, Sara G Danielli and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Yun Wei *Molecular Pathology Unit, Massachusetts General Research Institute, Harvard Medical School, Charlestown, MA, USA.
Luis Antonio Corchete Sánchez *Krantz Family Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA, USA.ORCID http://orcid.org/0000-0003-4577-8599
Sabateeshan Mathavarajah *Molecular Pathology Unit, Massachusetts General Research Institute, Harvard Medical School, Charlestown, MA, USA.
Diego AnteloMolecular Pathology Unit, Massachusetts General Research Institute, Harvard Medical School, Charlestown, MA, USA.
Shuze WangMolecular Pathology Unit, Massachusetts General Research Institute, Harvard Medical School, Charlestown, MA, USA.
Jihee LeeMolecular Pathology Unit, Massachusetts General Research Institute, Harvard Medical School, Charlestown, MA, USA.
Alexander Daiki WeissmanMolecular Pathology Unit, Massachusetts General Research Institute, Harvard Medical School, Charlestown, MA, USA.
Devika D KannambadiMolecular Pathology Unit, Massachusetts General Research Institute, Harvard Medical School, Charlestown, MA, USA.
Qian QinKrantz Family Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA, USA.ORCID http://orcid.org/0000-0002-2119-6263
Sara G DanielliBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Elisa J QuantinMolecular Pathology Unit, Massachusetts General Research Institute, Harvard Medical School, Charlestown, MA, USA.
Tiffany C EngMolecular Pathology Unit, Massachusetts General Research Institute, Harvard Medical School, Charlestown, MA, USA.
Alexandra VelosoMolecular Pathology Unit, Massachusetts General Research Institute, Harvard Medical School, Charlestown, MA, USA.ORCID http://orcid.org/0000-0001-5807-7578
Yueyang WangMolecular Pathology Unit, Massachusetts General Research Institute, Harvard Medical School, Charlestown, MA, USA.
Gunnlaugur P NeilsenCenter for Sarcoma and Connective Tissue Oncology, Department of Orthopedic Surgery, Massachusetts General Hospital, Boston, MA, USA.
Chuan YanInstitute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.ORCID http://orcid.org/0000-0002-0449-7072
Valerie Shiwen YangInstitute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Anand G PatelDepartment of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0002-1438-8275
Selene C KooDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0001-8459-2469
Patience OdeniyideDivision of Pediatric Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Christine A PratilasDivision of Pediatric Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-7116-0605
Miguel N RiveraMolecular Pathology Unit, Massachusetts General Research Institute, Harvard Medical School, Charlestown, MA, USA.ORCID http://orcid.org/0000-0002-3636-2113
Esther RheinbayMolecular Pathology Unit, Massachusetts General Research Institute, Harvard Medical School, Charlestown, MA, USA. erheinbay@mgh.harvard.edu.
David M LangenauMolecular Pathology Unit, Massachusetts General Research Institute, Harvard Medical School, Charlestown, MA, USA. dlangenau@mgh.harvard.edu.ORCID http://orcid.org/0000-0001-6664-8318

Funding

Oncogenic Drivers of Rhabdomyosarcoma Cell State, Cancer Stem Cells and MetastasisR01CA269213 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI David Michael Langenau · 2023 to 2026
$2.4M
Mechanisms of aggressive Rhabdomyosarcoma.R01CA276116 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI David Michael Langenau · 2023 to 2026
$2.1M
Dissecting Persistent Cell Populations in RhabdomyoscaromaK08CA286845 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Anand G Patel · 2025 to 2026
$580k
Chromatin regulators of stemness and therapy resistance in rhabdomyosarcomaK99CA278696 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WEI, YUN · 2023 to 2024
$356k
NCI NIH HHS K08 CA286845NCI NIH HHS K99 CA278696NCI NIH HHS R01 CA269213NCI NIH HHS R01 CA276116U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) 1K08CA286845U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) K99CA278696U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA269213U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA276116
6 · The paper itself

Abstract

Tumor growth and relapse are often driven by cancer stem cells, but self-renewal mechanisms and genetic mutations that elevate their number are not fully understood. Here, we show that recurrent L122R mutation (Leucine to Argine change at amino acid 122) in the DNA-binding site of the Myogenic Differentiation 1 (MYOD1) transcription factor increases cancer stem cell frequency in aggressive Spindle cell/sclerosing rhabdomyosarcoma. MYOD1

Indexed as

Drug Resistance, NeoplasmMyoD ProteinNeoplastic Stem CellsRhabdomyosarcomaAnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMiceMutationReceptor Tyrosine Kinase-like Orphan ReceptorsMyoD1 myogenic differentiation proteinMyoD ProteinReceptor Tyrosine Kinase-like Orphan Receptors

Identifiers

PMID42236477
PMCPMC13396186

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.